Quotes 5-day view Delayed Nasdaq
10/20/2020
10/21/2020
10/22/2020
10/23/2020
10/26/2020
Date
277.53(c)
272.6(c)
278.5(c)
281.42(c)
284.33 Last
141 637
245 345
292 447
202 810
112 237 Volume
-1.40% -1.78% +2.16% +1.05% +1.03% Change
Sales 2021
843 M - -
Net income 2021
181 M - -
Net cash position 2021
541 M - -
P/E ratio 2021
68,7x
Yield 2021
-
Sales 2022
1 015 M - -
Net income 2022
243 M - -
Net cash position 2022
838 M - -
P/E ratio 2022
52,5x
Yield 2022
-
Capitalization
12 677 M 12 677 M -
EV / Sales 2021
14,4x
EV / Sales 2022
11,7x
Nbr of Employees
1 536
Free-Float
92,2%
Abiomed, Inc. specializes in the development, manufacturing and marketing of medical devices to assist or replace the pumping function of the failing heart. Net sales break down by activity as follows:
- product sales (96.4%): heart pumps (Impella brand);
- service provision (3.6%): including preventive maintenance services.
The United States account for 86.4% of net sales.
Notations Surperformance© of Abiomed, Inc.
Trading Rating : Investor Rating :
All news about ABIOMED, INC.
News in other languages on ABIOMED, INC.
Big Tech drives S&P 500 to record high in coronavirus rally
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ABIOMED, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
9
Average target price
315,40 $
Last Close Price
281,42 $
Spread / Highest target
29,7%
Spread / Average Target
12,1%
Spread / Lowest Target
-22,9%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
